Literature DB >> 28025635

Comment on "Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography".

Xiulan Xue1, Shaohang Cai2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 28025635      PMCID: PMC5153461          DOI: 10.1155/2016/9343960

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


× No keyword cloud information.
We read with great interest the study conducted by Chen et al. [1]. The authors demonstrated that transient elastography (TE) is a nonpainful, convenient, and safe way to assess the liver injury after Fontan surgery. The data indicated that TE values were higher in Fontan patients versus controls (18.6 versus 4.7 Kpa, P < 0.001), although there was no association between TE values and patients age, time since Fontan surgery, or median Fontan circuit pressure. The study design was elegant and the finding was interesting. However, we may wonder whether the liver stiffness among Fontan patients may be biased by alanine aminotransferase (ALT). Numerous studies have examined the performance of TE in assessment of hepatic fibrosis. Among patients with normal ALT and bilirubin level, when TE value is more than 7.4 to 7.8 Kpa, the sensitivity and specificity to diagnosis of liver significant fibrosis (>F2) were 76–83% and 82–84%, and when TE value is more than 11.9 to 14.8 Kpa, the sensitivity and specificity to diagnosis of liver cirrhosis were 87–94% and 91–93% [2-4] (Table 1). In Chen's work, some Fontan patients' liver stiffness was higher than 30 Kpa, which seriously deviated from liver cirrhosis of general population. This intriguing result may be cause by the ALT levels. Studies have reported that performance of TE for fibrosis assessment was influenced seriously by ALT level and bilirubin level [5-7]. Liver stiffness value was well correlated with serum ALT level and higher liver stiffness was associated with higher serum ALT level. In Chen's work, the ALT levels among Fontan patients in the study were average 31.5 U/L from 12.0 to 54 U/L, significantly higher than control group with average 17.0 U/L from 12.0 to 32.0 U/L. That may bias the TE value. Hence, the reason why liver stiffness among Fontan patients was higher than control group may be not only because the level of liver fibrosis in Fontan patients is more severe than control group, but also because the ALT level is significantly higher in Fontan patients compared with control group. And that may explain the reason why TE value was not associated with time since Fontan surgery is with only P value of 0.06. Study has suggested that grouping patients according to ALT level is necessary for TE detection [8]. Although data from the study indicated that TE was efficacious for detecting liver fibrosis after Fontan surgery, stratifying patients according to ALT levels and comparing with control group with a similar ALT level may be much more convincing and interesting.
Table 1

Performance of transient elastography for detection advanced fibrosis and liver cirrhosis.

AuthorPatientsAdvanced fibrosis (>F2)Liver cirrhosis
Cut-off Se%Sp%Cut-offSe%Sp%
Lupsor et al. 20083247.4768411.98791
Arena et al. 20081507.8838214.89492
Platon et al. 201312027.4808413.29493

Se, sensitivity; SP, specificity.

However, data from the study have proven that TE was convenient and efficacious detection to diagnosis of liver fibrosis among Fontan patients. That is a valuable suggestion for real time clinical practice. Until now, studies focusing on monitoring the progress of liver fibrosis in patients after Fontan surgery by TE detection are limited and an optimal cut-off value of liver stiffness is missing. A prospective clinical trial is needed to find an optimal cut-off value to diagnosis of the progress of liver fibrosis after Fontan surgery. So clinical physician can take a timely medical intervention for those Fontan patients with serious liver fibrosis to prevent disease progress to end-stage liver disease, such as liver cirrhosis and hepatocellular carcinoma.
  8 in total

1.  Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B.

Authors:  Yong Peng Chen; Xie Er Liang; Qi Zhang; Jie Peng; You Fu Zhu; Wei Qun Wen; Jin Lin Hou
Journal:  J Gastroenterol Hepatol       Date:  2012-07       Impact factor: 4.029

2.  Performance of unidimensional transient elastography in staging chronic hepatitis C. Results from a cohort of 1,202 biopsied patients from one single center.

Authors:  Monica Lupsor Platon; Horia Stefanescu; Diana Feier; Anca Maniu; Radu Badea
Journal:  J Gastrointestin Liver Dis       Date:  2013-06       Impact factor: 2.008

3.  Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

Authors:  B Coco; F Oliveri; A M Maina; P Ciccorossi; R Sacco; P Colombatto; F Bonino; M R Brunetto
Journal:  J Viral Hepat       Date:  2007-05       Impact factor: 3.728

4.  Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases.

Authors:  Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Richard Hoi-Leong Chum; Henry Kai-Wing Chan; Kenneth Ka-Ki Lau; Angel Mei-Ling Chim; Karen Ka-Lam Yiu; Francis Ka-Leung Chan; Joseph Jao-Yao Sung; Henry Lik-Yuen Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2008-05-05       Impact factor: 11.382

5.  Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients.

Authors:  Monica Lupşor; Radu Badea; Horia Stefănescu; Mircea Grigorescu; Zeno Sparchez; Alexandru Serban; Horatiu Branda; Sorana Iancu; Anca Maniu
Journal:  J Gastrointestin Liver Dis       Date:  2008-06       Impact factor: 2.008

6.  Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage.

Authors:  Abdurrahman Sagir; Andreas Erhardt; Marcus Schmitt; Dieter Häussinger
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

7.  Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C.

Authors:  U Arena; F Vizzutti; J G Abraldes; G Corti; C Stasi; S Moscarella; S Milani; E Lorefice; A Petrarca; R G Romanelli; G Laffi; J Bosch; F Marra; M Pinzani
Journal:  Gut       Date:  2008-04-30       Impact factor: 23.059

8.  Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography.

Authors:  Becky Chen; Richard A Schreiber; Derek G Human; James E Potts; Orlee R Guttman
Journal:  Can J Gastroenterol Hepatol       Date:  2016-08-30
  8 in total
  20 in total

1.  Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan.

Authors:  Jing Sun; Yanfang Li; Xuying Sun; Youde Liu; Danxia Zheng; Lijuan Fan
Journal:  Exp Ther Med       Date:  2019-07-03       Impact factor: 2.447

2.  Predictors for advanced liver fibrosis in chronic hepatitis B virus infection with persistently normal or mildly elevated alanine aminotransferase.

Authors:  Dexin Wang; Ping Zhang; Min Zhang
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

3.  Response to: Comment on "Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography".

Authors:  Becky Chen; Richard A Schreiber; Derek G Human; James E Potts; Orlee R Guttman
Journal:  Can J Gastroenterol Hepatol       Date:  2017-02-08

4.  Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.

Authors:  Ya-Fei Guo; Jing-Xin Pan; Wei-Huang Zhuang
Journal:  Infect Agent Cancer       Date:  2018-12-12       Impact factor: 2.965

5.  Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B.

Authors:  Liguo Wang; Peng Chen; Chao Zheng
Journal:  Infect Drug Resist       Date:  2018-11-08       Impact factor: 4.003

6.  Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus.

Authors:  Hongli Zhao; Xiangxin Song; Zhang Li; Xinling Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

7.  Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy.

Authors:  Jianyong Zeng; Caixia Zheng; Hua Li
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

8.  Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study.

Authors:  Zhaoping Yan; Bing Qiao; Haifeng Zhang; Yanling Wang; Wei Gou
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

9.  Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission.

Authors:  Cuicui Ren; Lili Wang; Weihui Sun; Lei Ma; Zhi Dong; Anhua Hao; Lin Zhou; Fengzhu Li; Wenjie Ma
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

10.  A model combining TNM stage and tumor size shows utility in predicting recurrence among patients with hepatocellular carcinoma after resection.

Authors:  Yu Zhang; Shu-Wei Chen; Li-Li Liu; Xia Yang; Shao-Hang Cai; Jing-Ping Yun
Journal:  Cancer Manag Res       Date:  2018-09-20       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.